Swiss Franc: Market pricing challenges SNB stance – BNY
BNY’s Geoff Yu argues that Swiss Franc (CHF) positioning looks stretched as investors bet on policy tightening that the Swiss National Bank (SNB) is unlikely to deliver. He highlights subdued Swiss inflation, soft Gross Domestic Product (GDP) data and the risk that an European Central Bank (ECB) hike further dampens external demand. Yu notes that conditional inflation forecasts leave little justification for SNB rate hikes and sees policy remaining cautious.
Franc overheld versus Euro on policy mispricing
"As a generally zero- or even negative-yielding currency, the franc is rarely in an overheld position due to carry loss. There is passive hedging in place by CHF-denominated investors, but beyond regulatory mandates, we doubt such purchases are strongly encouraged – they conflict with the SNB’s general approach of deterring CHF purchases in normal times. Hence, when CHF moves into overheld territory on a standalone basis and is even better held than EUR, circumstances must be “abnormal.”"
"With the ECB moving toward a rate hike, circumstances are still very different, and there’s little chance the SNB can suddenly shift course. Headline inflation continues to run at relatively “normal” levels on a sequential basis, while Q1 GDP (sports-adjusted) surprised to the downside. There’s simply no demand-driven inflation impulse; if anything, the ECB’s hike will further slow demand among Switzerland’s key trading partners, and the SNB may even view hawkish policy as a risk to Swiss growth."
"Fundamentally, we continue to see a glaring inconsistency in how the market actually “prices” SNB policy. Interest rate futures still point to a 60% chance of a 25bp hike by the end of the year, perhaps in sympathy with the ECB, which is signaling a hawkish tilt. Despite current ECB guidance on rate hikes (which we expect to change as the Eurozone economy slows), options markets still point to marginally lower EUR/CHF via risk-reversals."
"Whatever the SNB’s own messaging, which we see as internally consistent, rate markets and FX options continue to point in opposite directions. If the SNB were truly worried about inflation, especially from external supply factors, there would be much greater tolerance of currency strength rather than an “increased willingness” to intervene. Ultimately, it comes down to the conditional inflation forecasts."
"We would also keep an eye on the Swiss Population Cap referendum, as its passage will have material implications for Swiss–EU relations in the long term."
(This article was created with the help of an Artificial Intelligence tool and reviewed by an editor.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
U.S. non-farm payrolls surge by 165,000 in October, far exceeding expectations! Unemployment rate unexpectedly drops to 4.1%, December rate hike expectations intensify
In October, US non-farm payrolls increased by 165,000, which is 2.5 times the Wall Street median forecast of 65,000 and represents an exceptionally strong deviation of about 5 standard deviations, exceeding the upper limit of all institutional forecast ranges. The unemployment rate unexpectedly fell from 4.2% to 4.1%, while the market had expected it to remain unchanged; average hourly wages also accelerated year-on-year growth to 3.1%. Meanwhile, the previous two months' non-farm payrolls were revised upwards by a total of 84,000. Following the release of the data, the yield on 2-year US Treasury bonds rose by 7 basis points, and the pricing of the probability of a Fed rate hike in December climbed to 70%.
AI Sell-off Hits Anthropic IPO, Potential Valuation Expected to Drop to $1.2–1.3 Trillion
The valuation range discussed by potential investors has been lowered from the previous high of $2 trillion to between $1.2 trillion and $1.3 trillion, and some strategists have even suggested going below $1 trillion to ensure safety. In the face of significant market volatility and financial concerns such as quarterly losses, Anthropic is facing tough decisions, including a discounted valuation, reducing the size of the offering, or postponing the listing.

Moderna Q3 revenue up 29% year-on-year, far exceeding expectations, raises full-year revenue growth guidance to 15%-25% | Earnings Report Insight
Moderna's Q3 revenue increased by 29% year-on-year to $1.31 billion, with profits significantly exceeding expectations. The company raised its 2026 revenue growth guidance to 15%-25%. The ramp-up of next-generation COVID-19 and flu vaccines, along with international market expansion, has driven performance improvement. Phase III data for the personalized cancer vaccine has also shown positive progress. The company is simultaneously advancing cost reduction and pipeline R&D, with year-end cash expectations significantly raised.
